Jian Pi Hua Tan Fang Reverses Trastuzumab Resistance of HER2‐Positive Gastric Cancer Through PI3K/AKT/mTOR Pathway: Integrating Network Pharmacology, Molecular Docking and Experimental Validation
JPHTF has the ability to overcome trastuzumab resistance in NCI-N87 cells through the regulation of the PI3K/AKT/mTOR pathway.
Authors
- Cong Wu (ORCID: https://orcid.org/0000-0003-4943-8786)
- Wenjing Bu
- Xin Li (ORCID: https://orcid.org/0000-0002-7138-0042)
- Youqi Xu (ORCID: https://orcid.org/0000-0003-0945-2954)
- Bo Shen (ORCID: https://orcid.org/0000-0001-6771-2406)
- Jia Hu (ORCID: https://orcid.org/0000-0002-5829-2638)
- Bo Zhang (ORCID: https://orcid.org/0000-0002-7853-979X)
- Xiaoyang Zhang (ORCID: https://orcid.org/0009-0006-7836-1465)
- Yongfang Ding
Institutions
- Nanjing University of Chinese Medicine (CN)
- Jiangsu Provincial Academy of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/iid3.70154
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18